Source facts
FDA issued an approval letter for JUXTAPID on 2026-02-27. The source metadata identifies NDA 203858 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
JUXTAPID — FDA Approval Letter (NDA 203858)
Issued to CHIESI. Application is approved as submitted.
Assyro regulatory brief
FreeWhat did FDA decide for JUXTAPID?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 203858.
- 3Submission: supplement.
- 4Sponsor: CHIESI.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the JUXTAPID approval letter
Is JUXTAPID FDA approved?
This letter documents an FDA approval action: FDA approved NDA 203858 for JUXTAPID, sponsored by CHIESI, on February 27, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 203858?
NDA 203858 is the application under which FDA issued this approval letter for JUXTAPID to CHIESI. The letter is dated February 27, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.